PL2073842T5 - Use of human cells of myeloid leukaemia origin for expression of antibodies - Google Patents

Use of human cells of myeloid leukaemia origin for expression of antibodies

Info

Publication number
PL2073842T5
PL2073842T5 PL07818090.8T PL07818090T PL2073842T5 PL 2073842 T5 PL2073842 T5 PL 2073842T5 PL 07818090 T PL07818090 T PL 07818090T PL 2073842 T5 PL2073842 T5 PL 2073842T5
Authority
PL
Poland
Prior art keywords
antibodies
expression
human cells
myeloid leukaemia
leukaemia origin
Prior art date
Application number
PL07818090.8T
Other languages
Polish (pl)
Other versions
PL2073842T3 (en
Inventor
Steffen Goletz
Antje Danielczyk
Hans Baumeister
Renate Stahn
Anja Löffler
Lars STÖCKL
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39157600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2073842(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06090171A external-priority patent/EP1900750A1/en
Priority claimed from EP06090190A external-priority patent/EP1911766A1/en
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Publication of PL2073842T3 publication Critical patent/PL2073842T3/en
Publication of PL2073842T5 publication Critical patent/PL2073842T5/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL07818090.8T 2006-09-10 2007-09-10 Use of human cells of myeloid leukaemia origin for expression of antibodies PL2073842T5 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP06090162 2006-09-10
EP06090171A EP1900750A1 (en) 2006-09-18 2006-09-18 Fully human high yield production system for improved antibodies
EP06090190A EP1911766A1 (en) 2006-10-13 2006-10-13 Use of human cells of myeloid leukaemia origin for expression of antibodies
EP07090094 2007-05-04
EP07818090.8A EP2073842B2 (en) 2006-09-10 2007-09-10 Use of human cells of myeloid leukaemia origin for expression of antibodies
PCT/EP2007/007877 WO2008028686A2 (en) 2006-09-10 2007-09-10 Use of human cells of myeloid leukaemia origin for expression of antibodies

Publications (2)

Publication Number Publication Date
PL2073842T3 PL2073842T3 (en) 2015-06-30
PL2073842T5 true PL2073842T5 (en) 2024-12-02

Family

ID=39157600

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07818090.8T PL2073842T5 (en) 2006-09-10 2007-09-10 Use of human cells of myeloid leukaemia origin for expression of antibodies

Country Status (25)

Country Link
US (3) US9051356B2 (en)
EP (5) EP2073842B2 (en)
JP (3) JP5767779B2 (en)
KR (3) KR20150126730A (en)
CN (1) CN103436574B (en)
AU (1) AU2007294122B2 (en)
BR (1) BRPI0716997B8 (en)
CA (1) CA2662226C (en)
CU (1) CU23791A3 (en)
CY (1) CY1116279T1 (en)
DK (2) DK2073842T4 (en)
EA (1) EA017622B1 (en)
ES (2) ES2620261T3 (en)
FI (1) FI2073842T4 (en)
HR (1) HRP20150307T1 (en)
IL (1) IL197459A (en)
MX (1) MX2009002388A (en)
NZ (1) NZ575974A (en)
PL (1) PL2073842T5 (en)
PT (1) PT2073842E (en)
RS (1) RS53861B1 (en)
SG (1) SG174792A1 (en)
SI (1) SI2073842T1 (en)
WO (1) WO2008028686A2 (en)
ZA (1) ZA201001903B (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3528611B2 (en) * 1998-07-16 2004-05-17 Ｊｆｅスチール株式会社 Method and apparatus for cutting binding material
PT2073842E (en) 2006-09-10 2015-04-07 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
WO2008135259A2 (en) * 2007-05-04 2008-11-13 Glycotope Gmbh Antibody molecule composition
GB0812277D0 (en) * 2008-07-04 2008-08-13 Fusion Antibodies Ltd Antibody and uses thereof
NZ593816A (en) † 2009-01-22 2012-11-30 Momenta Pharmaceuticals Inc Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from cho cells
US20120100576A1 (en) 2009-07-08 2012-04-26 Glycotope Gmbh Perfusion bioreactor
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
CN103119064B (en) * 2010-08-10 2018-09-04 葛莱高托普有限公司 Fab glycosylated antibodies
US9051370B2 (en) 2010-08-10 2015-06-09 Glycotope Gmbh Humanized EGFR antibodies
WO2012020059A1 (en) 2010-08-10 2012-02-16 Glycotope Gmbh Humanized egfr antibodies
WO2012085162A1 (en) 2010-12-21 2012-06-28 Glycotope Gmbh Methods for culturing human myeloid leukaemia cells and cells derived therefrom
EP3501546A3 (en) 2011-04-21 2019-09-18 Seattle Genetics, Inc. Cysteine drug conjugates and use of same
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2844435A1 (en) * 2011-08-10 2013-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated antibodies
JP6148671B2 (en) 2011-08-22 2017-06-14 グリコトープ ゲーエムベーハー Microorganisms that carry tumor antigens
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
EA201590237A1 (en) * 2012-07-18 2015-05-29 Гликотоп Гмбх NEW METHODS OF ANTIBODY TREATMENT AGAINST HER2 WITH LOW FUZOZYLATION
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150353959A1 (en) 2013-01-18 2015-12-10 Glycotope Gmbh Peptides for enhancing protein expression
CN105308071A (en) * 2013-02-13 2016-02-03 法国化学与生物科技实验室 Highly galactosylated anti-her2 antibodies and uses thereof
BR112015019348A2 (en) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement METHODS FOR PRODUCING GLYCOSYLATION MODIFIED AND SIALYLATION ENHANCED PROTEIN, TO ENHANCE SIALYL TRANSFERASE ACTIVITY IN THE MAMMARY GLAND AND TO PRODUCE SIALYL TRANSFERASE, GLYCOSYLATION MODIFIED PROTEIN OR SIALYLATION ENHANCED PROTEIN, COMPOSITION, SIALYL TRANSFERASE, MAMMALIAN, AND TRANSGENE MAMMARY EPITHELIAL
AU2014217561B2 (en) * 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
MX2015010429A (en) * 2013-02-13 2016-05-16 Lab Francais Du Fractionnement Cetuximab with modified glycosylation and uses thereof.
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
CN105378099B (en) 2013-03-14 2021-05-11 雅培制药有限公司 HCV core lipid binding domain monoclonal antibodies
JP6505076B2 (en) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ HCV antigen-antibody combination assay and methods and compositions for use therein
EP2970947A4 (en) 2013-03-14 2016-10-12 Abbott Lab Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
ES2834113T3 (en) 2013-03-15 2021-06-16 H Lundbeck As Antibody purification and purity monitoring
KR20150144804A (en) 2013-04-22 2015-12-28 글리코토페 게엠베하 Anti-cancer treatments with anti-egfr antibodies having a low fucosylation
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) * 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2934617A1 (en) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with kinesin spindle protein (ksp)
CN106102749B (en) * 2014-03-05 2019-07-12 奥特吉尼克斯制药公司 Sialydated glycoproteins composition and application thereof
US20150307546A1 (en) * 2014-04-29 2015-10-29 Georgia Tech Research Corporation Thermo-responsive lectin-elp fusion binding ligands for glycoprotein purification by affinity precipitation
CN105820248A (en) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 Method for preparing novel anti-EGFR monoclonal antibody and application thereof
LU92659B1 (en) 2015-02-23 2016-08-24 Glycotope Gmbh Glycooptimized antibody drug conjugates
FR3034420A1 (en) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement ANTI-CD303 MONOCLONAL ANTIBODIES
EP3277807B1 (en) 2015-03-31 2019-12-11 Glycotope GmbH Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters
WO2016198499A1 (en) 2015-06-09 2016-12-15 Glycotope Gmbh IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN107921288A (en) 2015-06-23 2018-04-17 拜耳医药股份有限公司 The targeting conjugate of KSP inhibitor
WO2016207328A1 (en) 2015-06-24 2016-12-29 Glycotope Gmbh PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
FR3038517B1 (en) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
WO2017044866A2 (en) * 2015-09-11 2017-03-16 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017070460A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
WO2017162733A1 (en) * 2016-03-22 2017-09-28 Glycotope Gmbh Iga antibodies with enhanced stability
JP7251981B2 (en) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト Prodrugs of Cytotoxic Active Agents with Enzymatic Cleavage Groups
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
EP3472338B1 (en) 2016-06-20 2024-05-22 Octapharma AG Means and methods for modifying multiple alleles
FR3060395B1 (en) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies COMBINATION OF ANTI-CD303 AND ANTI-HER2 ANTIBODIES
FR3060394B1 (en) 2016-12-16 2019-05-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies COMBINATION OF ANTI-CD303 AND ANTI-AMHRII ANTIBODIES
KR102556826B1 (en) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 Antibody drug conjugates (ADCs) with enzymatically cleavable groups
WO2018114804A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3574015A1 (en) * 2017-01-27 2019-12-04 Glycotope GmbH Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
JP6829357B2 (en) * 2017-03-17 2021-02-10 住友ベークライト株式会社 Antibody sugar chain detection method
EP3601348A1 (en) 2017-03-29 2020-02-05 Glycotope GmbH Humanized anti-cd40 antibodies
CA3057758A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Pd-l1 and ta-muc1 antibodies
CA3055438A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
JP2020534814A (en) 2017-09-06 2020-12-03 エアウェイ・セラピューティクス・インコーポレイテッド Methods, compositions, and cells for preparing surfactant protein D (SP-D)
KR102831403B1 (en) 2017-09-06 2025-07-09 에어웨이 테라퓨틱스, 아이엔씨. Method and composition for preparing surfactant protein D (SP-D)
EP3759144A1 (en) 2018-03-01 2021-01-06 Glycotope GmbH Fusion protein constructs comprising an anti-muc1 antibody and il-15
HRP20240756T1 (en) 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate
CN118221825A (en) * 2019-07-26 2024-06-21 Abl生物公司 Anti-EGFR/anti-4-1BB bispecific antibody, use, preparation method and encoding polynucleotide
KR20240007293A (en) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. Anti-vegf protein compositions and methods for producing the same
MX2022013812A (en) 2020-05-08 2022-12-15 Regeneron Pharma Vegf traps and mini-traps and methods for treating ocular disorders and cancer.
AU2021298824A1 (en) 2020-06-30 2023-01-19 Pentixapharm Ag Humanized antibodies against lewis Y
IL315431A (en) 2022-03-16 2024-11-01 Pentixapharm Ag Antibodies against LYPD3
WO2025099324A1 (en) 2023-11-10 2025-05-15 Tixapharm Ag Antibodies against cd44
AU2024402617A1 (en) 2023-12-19 2026-05-14 Pentixapharm Ag Antibodies against cd24

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
KR850004274A (en) 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US4931275A (en) 1985-12-02 1990-06-05 Yeda Research & Development Co., Ltd. Anti-tumor vaccines and their preparation
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
AU664030B2 (en) 1991-02-27 1995-11-02 Micromet Ag Serine-rich peptide linkers
EP0636029B1 (en) 1992-04-13 2000-11-08 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
ATE301201T1 (en) 1993-06-07 2005-08-15 Vical Inc PLASMIDS USABLE FOR GENE THERAPY
DE4329004A1 (en) 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoclonal antibodies against the Thomsen-Friedenreich antigen, their preparation and their use for tumour detection
AU7965694A (en) * 1993-10-15 1995-05-04 Curators Of The University Of Missouri, The Dna encoding the human p2u receptor and null cells expressing p2u receptors
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5888773A (en) * 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997040182A1 (en) 1996-04-19 1997-10-30 Gabriele Pecher Genetically transfected human dendritic cells, their production and use, preferably as vaccines
CA2309766C (en) 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
AUPP816899A0 (en) 1999-01-14 1999-02-11 Food Technology Innovations Pty Limited Improved microbial products
CA2363297C (en) 1999-03-02 2011-08-09 Michael J. Betenbaugh Engineering intracellular sialylation pathways
JP4488579B2 (en) * 1999-03-30 2010-06-23 日本たばこ産業株式会社 Method for producing monoclonal antibody
AU754808B2 (en) * 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
PT1176195E (en) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule
DE60018761T2 (en) 1999-08-18 2006-02-02 Altarex Medical Corp., Edmonton THERAPEUTIC ANTIBODY AGAINST MUC-1 ANTIGEN AND METHOD OF USE THEREOF
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
WO2001023421A2 (en) 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
FR2809312B1 (en) 2000-05-25 2002-07-12 Gervais Danone Sa USE OF L. CASEI IN IMMUNOSTIMULATING COMPOSITIONS
WO2002030954A1 (en) * 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
KR100866199B1 (en) 2001-02-01 2008-10-30 가부시끼가이샤 야구르트혼샤 Intestinal Reach Evaluation Method of Bifidobacterium Bacteria in Fermented Milk Food and Beverage
WO2003016329A2 (en) 2001-08-17 2003-02-27 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Glycoconjugates of sialic acid derivates, methods for their production and use thereof
DE10139428A1 (en) 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Preparation of dendritic cells, useful e.g. as antitumor or antimicrobial vaccines, by treating CD124- and CD116-positive cells with stimulatory molecules
UA87433C2 (en) * 2001-10-22 2009-07-27 Еплайд Рісьорч Системз Ерс Холдінг Н.В. Gonadotropines for stimulation of folliculogenesis
GB0125473D0 (en) 2001-10-24 2001-12-12 Syngenta Ltd Chemical process
WO2003044051A1 (en) 2001-11-20 2003-05-30 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
DK1529060T3 (en) 2002-07-22 2014-12-15 Glycotope Gmbh PROCEDURE FOR PREPARING AN IMMUNSTIMULATORY MUCIN (MUC1)
US7595192B2 (en) 2002-08-16 2009-09-29 Glycotype Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
DE10256900A1 (en) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumor-specific recognition molecules
DE10303664A1 (en) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Detection molecules for the treatment and detection of tumors
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1654353B1 (en) 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
FR2861080B1 (en) 2003-10-20 2006-02-17 Lab Francais Du Fractionnement ANTIBODIES HAVING AN OPTIMIZED FUCOSE AND GALACTOSE RATE
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
EP1725673A1 (en) * 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
US7374755B2 (en) 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
KR20080104143A (en) * 2006-02-14 2008-12-01 코닌클리케 필립스 일렉트로닉스 엔.브이. Bit detection for reading optical discs
WO2007124992A1 (en) 2006-04-28 2007-11-08 Unilever N.V. Method of manufacturing a cultured edible product comprising omega-3 polyunsaturated fatty acids
PT2073842E (en) 2006-09-10 2015-04-07 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1911766A1 (en) 2006-10-13 2008-04-16 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
EP1900750A1 (en) 2006-09-18 2008-03-19 Glycotope Gmbh Fully human high yield production system for improved antibodies
EP1920782A1 (en) 2006-11-10 2008-05-14 Glycotope Gmbh Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
CA2722738C (en) 2008-05-13 2017-04-25 Glycotope Gmbh Fermentation process
EP2420515A4 (en) 2009-04-16 2013-08-28 Univ Tokyo DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US20150353959A1 (en) 2013-01-18 2015-12-10 Glycotope Gmbh Peptides for enhancing protein expression
JP2015138634A (en) 2014-01-22 2015-07-30 株式会社オートネットワーク技術研究所 Electric wire with terminal fitting and method for manufacturing the same

Also Published As

Publication number Publication date
SG174792A1 (en) 2011-10-28
EP2428224A3 (en) 2012-05-09
ES2533964T5 (en) 2024-05-09
ZA201001903B (en) 2010-11-24
NZ575974A (en) 2012-03-30
IL197459A (en) 2015-08-31
KR20170021375A (en) 2017-02-27
HRP20150307T1 (en) 2015-04-24
KR20090077911A (en) 2009-07-16
SI2073842T1 (en) 2015-05-29
US9051356B2 (en) 2015-06-09
EP2428225A2 (en) 2012-03-14
JP6166303B2 (en) 2017-07-19
US20150368363A1 (en) 2015-12-24
EP2428224A2 (en) 2012-03-14
JP2010502204A (en) 2010-01-28
BRPI0716997B1 (en) 2020-06-02
JP2017123879A (en) 2017-07-20
US10280230B2 (en) 2019-05-07
EA017622B1 (en) 2013-01-30
ES2620261T3 (en) 2017-06-28
BRPI0716997A8 (en) 2019-02-05
FI2073842T4 (en) 2024-01-15
JP2015146819A (en) 2015-08-20
KR101603632B1 (en) 2016-03-16
DK2428224T3 (en) 2017-03-27
US20190359731A1 (en) 2019-11-28
PL2073842T3 (en) 2015-06-30
EP2428224B1 (en) 2016-12-21
CN103436574B (en) 2016-08-10
RS53861B1 (en) 2015-08-31
WO2008028686A3 (en) 2008-06-12
PT2073842E (en) 2015-04-07
BRPI0716997A2 (en) 2013-10-15
CN103436574A (en) 2013-12-11
EP2073842A2 (en) 2009-07-01
CA2662226A1 (en) 2008-03-13
EP2428225A3 (en) 2012-05-09
AU2007294122A1 (en) 2008-03-13
EA200970263A1 (en) 2009-08-28
ES2533964T3 (en) 2015-04-16
BRPI0716997B8 (en) 2021-05-25
CA2662226C (en) 2020-08-04
KR20150126730A (en) 2015-11-12
MX2009002388A (en) 2009-06-02
US20100028947A1 (en) 2010-02-04
JP5767779B2 (en) 2015-08-19
DK2073842T4 (en) 2024-01-15
EP2428223A3 (en) 2012-05-16
DK2073842T3 (en) 2015-04-13
WO2008028686A2 (en) 2008-03-13
AU2007294122B2 (en) 2013-03-07
CU23791A3 (en) 2012-03-15
EP2073842B1 (en) 2014-12-31
EP2073842B2 (en) 2023-10-18
IL197459A0 (en) 2011-08-01
CY1116279T1 (en) 2017-02-08
EP2428223A2 (en) 2012-03-14
EP3539981A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
PL2073842T3 (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
HRP20181616T1 (en) Fully human anti-vap-1 monoclonal antibodies
IL193604A0 (en) Methods of using antibodies against human il-22
ZA201008952B (en) Compositions and methods of use for therapeutic antibodies
PL2949666T3 (en) Human anti-alpha-synuclein antibodies
IL196701A0 (en) HUMAN ANTIBODIES TO ErbB2
HUE046564T2 (en) Anti-factor xi monoclonal antibodies and methods of use thereof
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
ZA201103723B (en) Human antibodies against human tissue factor
PL2631241T3 (en) Process for generation of protein and uses thereof
PL2037950T3 (en) Further medical uses of antisecretory protein
IL212795A0 (en) Fully human antibodies against n-cadherin
ZA200901912B (en) Use of human cells of myeloid leukaemia origin for expression of antibodies
GB0605950D0 (en) Device for prediction of human or other mammalian labour onset
HRP20190159T1 (en) Human anti-alpha-synuclein antibodies
HU0600053V0 (en) Electro-optical device for screening of skin diseases
HU3350U (en) Device for covered introduction of scalpels
TWM300387U (en) Improved structure of cupulate holder
SG10202006468XA (en) Human antibodies against human tissue factor
HU0600626D0 (en) New medical use of mononucleosides
GB0720136D0 (en) Treatment of blood disorded